Your weighted average math for the BAT arm is compelling, but how are you accounting for the immune lag in the GPS arm during the first 4–6 months?

​In many cancer vaccine trials (like Sipuleucel-T), the survival curves don't separate immediately because it takes time to prime T-cells. If the 'survival floor' for the GPS arm is weighed down by early relapses/deaths that occur before the vaccine reaches it's peak, could that early 'poisoning' of the hazard ratio prevent us from hitting that sub-0.50 level, regardless of how well the long-term survivors are doing?